Rational Design of Toxoid Vaccine Candidates for Leukocidin AB (LukAB).

(SA) infections cause high mortality and morbidity in humans. Being central to its pathogenesis, thwarts the host defense by secreting a myriad of virulence factors, including bicomponent, pore-forming leukotoxins. While all vaccine development efforts that aimed at achieving opsonophagocytic killing have failed, targeting virulence by toxoid vaccines represents a novel approach to preventing mortality and morbidity that are caused by SA.